Baseline cytokines and programmed death-ligand 1 prognostic value in advanced gastric cancer with sintilimab plus chemotherapy

doi:10.3748/wjg.120447

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 40

This Article

(6)

(4)

(0)

(85)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Oct 28, 2026; 32(40): 120447
Published online Oct 28, 2026. doi: 10.3748/wjg.120447

Full Size Figure Download Figure

Figure 1 Receiver operating characteristic curves for prediction of death by pre-immunotherapy cytokine levels in gastric cancer patients. ROC: Receiver operating characteristic; AUC: Area under the curve; IL: Interleukin; OS: Overall survival.

Citation: Li YC, Pan D, Liu HN, Pei ZC, Li YQ, Han ZX, Liu WL. Baseline cytokines and programmed death-ligand 1 prognostic value in advanced gastric cancer with sintilimab plus chemotherapy. World J Gastroenterol 2026; 32(40): 120447
URL: https://www.wjgnet.com/1007-9327/full/v32/i40/120447.htm
DOI: https://dx.doi.org/10.3748/wjg.120447

Li YC, Pan D, Liu HN, Pei ZC, Li YQ, Han ZX, Liu WL. Baseline cytokines and programmed death-ligand 1 prognostic value in advanced gastric cancer with sintilimab plus chemotherapy. World J Gastroenterol 2026; 32(40): 120447 [DOI: 10.3748/wjg.120447]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.